Musculoskeletal Diseases

Nervous System Diseases

Symptoms and General Pathology

All Conditions

Myalgia

All Drugs and Chemicals

Amino Acids

Tyrosine Kinase Inhibitors

Tyrosine

Any patient with solid tumor and treated by Thyrosine Kinase Inhibitor for at least 1 week

CPK dosage during a blood sample realized at least one week after the begining of the treatment

CPK dosage

Examination of the patient for myalgia, cramps, medical history and concomitant medication

Clinical exam

Antoine ADENIS, MD, PhD

This study describes the elevation of CPK in patient treated for solid tumors by TKI

Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases

National Study of Prevalence of Creatinine Phosphokinase (CPK) Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases (TKI)

Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL

To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase

Centre Oscar Lambret

Neoplasms

Skin and Connective Tissue Diseases

Immune System Diseases

Breast Neoplasms

Hypersensitivity

Breast Diseases

Skin Diseases

Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis

Blood sample

Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians

Yazid BELKACEMI, MD

25 patients, treated by brachytherapy in a phase II study "Mammosite" (from 2003 to 2005), will be asked to attend a clinical exam in order to evaluate the late cutaneous toxicity due to brachytherapy.

During this consultation, a blood sample will be taken for analysis ( rate of CD8 T-Lymphocyte Apoptosis)

This is an interventional study for the french law

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases	NCT01248429	Cancer Solid Tumor	CPK dosage Clinical exam	18 Years -	Centre Oscar Lambret
Prevalence of Creatinine Phosphokinase Increase in Patients With Solid Tumors Treated by Inhibitors of Tyrosine Kinases	NCT01248429	Cancer Solid Tumor	CPK dosage Clinical exam	18 Years -	Centre Oscar Lambret
Research for Predictive Biologic Parameters of Cutaneous Hypersensitivity After Brachytherapy in Breast Cancer	NCT00922961	Breast Cancer	Blood sample Clinical exam	60 Years -	Centre Oscar Lambret

Spots Global Cancer Trial Database for clinical exam